Improving the lives of people suffering from mental illness and substance use disorders

Developing improved pharmaceuticals based on innovative drug delivery technologies

Providing evidence-based digital therapies to improve treatment outcomes

What we do

Pharmaceuticals

Pharmaceuticals

Commercializing and developing pharmaceuticals addressing large unmet needs

Digital Therapeutics

Digital Therapeutics

Product portfolio of scientifically proven digital therapies

Mental illness & substance use disorders

Mental illness & substance use disorders

Focusing on areas of great human suffering with wider societal implications

We Care

Shedding light on lives affected by addiction and the road to recovery

Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.

Key News

JULY 16, 2021
Our overdose rescue medication OX124 enters pivotal study

JULY 15, 2021
Announcement of the Q2 2021 Interim Report

JULY 12, 2021
Commercial partnership agreement signed with Sober Grid for vorvida® and deprexis®

Orexo Social

16 July 2021

NEWS: The pivotal study for our rescue medication OX124 has been initiated. A New Drug Application is expected to b… https://t.co/AobekYZrVv

15 July 2021

Q2 Interim Report – In O2 we saw increased activities in R&D and the DTx business. The greatest highlight was that… https://t.co/nLDmtFzEqz

12 July 2021

Today we announce a commercial partnership has been signed with @SoberGridApp the largest social media community fo… https://t.co/rgn1kjo6Tf

Our history

Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.

Financial Snapshot

Group net revenues

585 MSEK

LTM1

Group EBITDA

-76 MSEK

LTM1

US Pharma segment EBIT

295 MSEK

LTM1

Cash position

680 MSEK

Q1 2021

1 Last Twelve Months, Q320-Q221, for more information about financial development Link